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designed including 5 elements deﬁning quality, clustered into
three criteria, and 12 components covering types of evidence
required by decision-making bodies worldwide. A scoring
process was developed based on international scientiﬁc standards
in each ﬁeld of research covered. To quantify the intrinsic value
of an intervention, a multi-criteria decision analysis (MCDA)
matrix was designed encompassing 15 value components.
Scoring, which depends on the value system of the evaluator, was
designed to allow inclusion of perspectives of a representative
group of health care stakeholders. An integrated process to apply
matrices was established. The EVIDEM methodology can be
applied retrospectively to explore the contribution of quality of
evidence and intrinsic value to past coverage decisions. Prospec-
tively, matrices can be adapted to speciﬁc needs of decision-
makers and applied to evaluate new health care interventions.
The matrices also provide a practical collaborative frame-
work for those who generate data and those who need data
to make decisions, ultimately facilitating future health care
decision-making.
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MEDICATION ADHERENCE:A CONCEPTUAL REVIEW
Nadkarni A, Kucukarslan SN, Gaither CA, Bagozzi RP
University of Michigan, Ann Arbor, MI, USA
Adherence is an important element in the medical ﬁeld since it is
thought to be the link between treatment and outcomes. Adher-
ence to medications has been extensively researched and it is
evident that non-adherence is common across most disease
states. These studies vary by the conceptual deﬁnitions of adher-
ence behavior and by the research paradigms. The objectives of
this presentation are to review the conceptual deﬁnitions used in
adherence research and to review the theoretical frameworks
used to explain mediation adherence behavior. Compliance,
adherence, and concordance are used interchangeably in the
medical, health behavior, and pharmacy literature. It is important
to compare and contrast these terms to study speciﬁc health
behavior. These terms reﬂect different philosophies of medicine
with respect to the provider-patient relationship. Conceptually,
adherence, compliance and concordance differ in the amount of
patient involvement and participation, that may be depicted
along a continuum of patient involvement- with compliance
depicting no patient involvement, concordance depicting patients
as being equal partners in their treatment and adherence lying
somewhere in between. Consistent use of these concepts will
move the science toward understanding speciﬁc patient behavior
and its antecedents.
Much of the adherence research published in the medical and
pharmacy journals does not include a theoretical framework.
The non-theoretical approach to adherence research is partly to
blame for the lack conceptual clarity and underscores the need to
incorporate a theoretical basis in adherence research. Prominent
theories in adherence research include expectancy-values models
like the health belief model, the transtheoretical model, and the
self-regulation theory. Other promising models include the medi-
cation adherence model, the interaction model of client behavior
and the therapeutic decision model. The strengths and weak-
nesses of each are presented. Finally, recommendations for
researchers of medication adherence include using a theoretical
framework and conducting longitudinal studies are provided.
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OBJECTIVE: Clinical evidence is often reported as an average
treatment effect across a large population. This is appropriate if
all patients experience the same effect from a given treatment.
However, more often, different patients experience different
outcomes on the same medication. If this is true, then averaging
the effects of treatment obscures the outcomes received by most
patients. It also makes it difﬁcult for physicians to utilize this
evidence to select the most appropriate treatment for individual
patients. This interpretation of average outcomes by physicians
leads to geographic variation, inappropriate care, and increased
health care costs. An essential step towards optimizing therapy
is to provide evidence that recognizes inter-individual differ-
ences in drug response. METHODS: The PPS is deﬁned as the
expected outcome (on control) given the individual’s covariates.
To calculate the PPS, the outcome of interest is regressed on the
covariates for those patients treated with the control(Drug A).
Using the coefﬁcients from this model, in conjunction with
patient characteristics, the PPS is computed for all patients; as
if every patient was a member of the control group. Variations
in treatment effect are then identiﬁed across subgroups by par-
titioning patients, according to PPS, into strata and calculat-
ing the treatment effect within each stratum. This analysis
is repeated using the alternative treatment (Drug B) as the
control. By identifying and comparing the stratum that receives
the optimal beneﬁt from each treatment, the patient character-
istics that are uniquely associated with success on Drug A and
Drug B can be determined. RESULTS: To demonstrate the use
of the PPS, a convenient sample of California Medicaid beneﬁ-
ciaries diagnosed with schizophrenia will be used. CONCLU-
SIONS: The outlined approach will allow physicians to more
accurately prescribe the most beneﬁcial treatment for each and
every patient, by linking patient characteristics to treatment
success.
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OBJECTIVES: The completion of the human genome project
has not provided the answer to genetic disease that was
expected and a large amount of research is still being con-
ducted into the treatment of genetically-linked disorders. The
rationale of this review was to investigate the proportion of
research conducted within eight genetically-linked disorders
across time (Alzheimer’s disease [AD], Crohn’s disease [CD],
cystic ﬁbrosis [CF], haemophilia, Huntington’s disease [HD],
muscular dystrophy [MD], Obesity, Sickle cell anaemia [SCA])
and to predict likely areas of growth within the selected disor-
ders. METHODS: A citation search was conducted in Medline
on December 12, 2007. A ﬁlter for RCTs was implemented to
provide an estimate of clinical interest in a given disease for the
years 1951–2005 (5-yearly time periods). RESULTS: A total of
706,660 probable RCT citations were retrieved, with 20,787
relating to the selected disorders. Over time, the rate of increase
of probable RCTs relating to these genetically-linked disorders
is not signiﬁcantly different from the general increase in RCTs
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(t = -0.09, p = 0.93). Probable RCTs in these areas now
account for 4% of all RCTs compared to 1.6% in 1956–60.
Advances in mono-factorial disorders such as CF, Haemophilia,
HD, MD and SCA, have tended to remain relatively constant
across 50 years, whilst multi-factorial diseases such as AD and
CD, continue to attract signiﬁcant interest. Obesity has
attracted an ever increasing number of RCTs. CONCLU-
SIONS: Trials of new treatments within the selected diseases
were expected to increase; however, results reported no evi-
dence of increased research (within the selected disorders) fol-
lowing the identiﬁcation of the causative gene(s). A greater
interest appeared to be directed towards diseases with gene-
environment interaction i.e. obesity. Further development of
this analysis may assist identiﬁcation of genetic research invest-
ments which can translate most effectively to improved clinical
practice.
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Discovering and developing drugs is a risky process that requires
a great deal of both time and money. To gain competitive advan-
tage, companies must establish the health economic viability of
the product and adapt development plans effectively to meet
market access requirements. To present a conceptual model that
optimizes the economic viability of potential new drugs by iden-
tifying useful properties and obtaining clinical, economic, and
quality-of-life data as early as possible in the product develop-
ment cycle. The matrix is formed by two drug characteristics
of primary importance: indication and mechanism of action
(MOA). Four scenarios arise from this matrix: I = New Market
Entry (drugs having both novel MOA and indication),
II = Product Development (new MOAs for existing indications),
III = Market Expansion (existing MOA but new indication), and
IV = Market Penetration (existing MOA and existing indication).
Economic viability incorporates the following six parameters:
efﬁcacy, tolerability/safety, QOL, pricing, effectiveness, and for-
mulation. To optimize a product’s economic viability, sponsors
should evaluate, based on type of scenario and its requirements
for these six parameters, the health economic challenges ahead to
be overcome in order to achieve successful reimbursement. Drugs
in Scenario I fulﬁll an unmet therapeutic need and are therefore
highly desired. Economic viability for these products is high.
Those with novel MOAs are also highly valued, as they could
treat wider ranges of patients or those who fail other regimens.
Compounds in Scenario IV pose the greatest challenges for health
economic viability. The product is considered a ‘me too’ and,
therefore, there is an increased focus on added value relative to
existing products. Using this matrix can identify early the
optimal position of a new drug, the data required, and when the
data should be collected and veriﬁed. Consequently, development
can be made efﬁcient, with reduced waste of resources and funds.
CARDIOVASCULAR DISORDERS—
Clinical Outcomes Studies
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OBJECTIVE: Studies have shown that increased co-morbidity is
associated with poor pharmacological adherence. We undertook
to determine the feasibility of using the modiﬁed RxRisk-V
co-morbidity index to predict adherence to lipid lowering
therapy (LLT). METHODS: Using RxAmerica data, patients
18 years and with 18 months of continuous health plan
enrollment from 2001–2005 were included in the analysis if they
were ‘new starts’ with any class of LLT, deﬁned as no prior
treatment in the class for six months. Adherence ratios (deﬁned
as proportions of drug-available days during the follow-up
period) were calculated and patients with adherence ratios0.80
were considered adherent to LLT. Using a modiﬁed RxRisk-V,
co-morbid conditions (CCs) were identiﬁed based on one-year of
prescription claims prior to the index LLT prescription. Multi-
variable logistic regression was used to estimate the age- and
sex-adjusted odds for adherence associated with various levels of
disease co-morbidity. RESULTS: A total of 19,458 patients were
identiﬁed as new starts with an LLT class. The mean age of
patients was 55 years (SD 12.1), 48% were females, and 43%
had 3 CCs. Results of the regression analysis showed that
patients with 1–2 CCs were less likely to be adherent (OR: 0.90;
CI: 0.83–0.99) compared to patients with no CCs. Patients with
3 CCs were more likely to be adherent (OR: 1.10; CI: 1.01–
1.18). The OR for adherence was signiﬁcantly decreased for
individuals with anxiety and tension, pain disorders, and tuber-
culosis. The OR was signiﬁcantly increased for patients with
cardiovascular diseases, psychiatric disorders, gastric acid dis-
orders, and others. CONCLUSION: These results show that
the relationship between adherence and degree of co-morbidity
takes a U-shaped distribution; patients with lower levels of
co-morbidity are less adherent compared to patients with no
co-morbidity, and patients with higher levels of co-morbidity are
more adherent.
PCV2
STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED
ACCORDINGTO NATIONAL LIPIDTREATMENT GUIDELINES
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OBJECTIVE: The objective of the analysis was to evaluate
impact of adherence to lipid treatment guidelines [National Cho-
lesterol Education Program’s Third Report on Detection, Evalu-
ation, and Treatment of High Blood Cholesterol and Adult
Treatment Panel’s (NCEP-ATP III)] on stroke events in managed
care patients. METHODS: Patients with laboratory values
for low-density lipoprotein-cholesterol (LDL-C), high-density
lipoprotein-cholesterol (HDL-C), & triglycerides (TG) between
January 1, 2003-December 31, 2005 [index date], no lipid
therapy 6-months pre-index date, and minimum 12 months
health plan eligibility pre- and post-index date were analyzed
using a large integrated United States managed care database.
Patients were classiﬁed as appropriately (AM) or inappropriately
managed (IAM) using baseline lipid levels and the ﬁrst post-index
follow-up lipid panel (goal attainment irrespective of therapy),
and risk stratiﬁcation per NCEP-ATP III guidelines. Post-index,
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